Oncolytics Biotech Voluntarily Delists from Toronto Stock Exchange to Focus on U.S. Operations
核心洞察
Oncolytics Biotech announced voluntary delisting from the Toronto Stock Exchange effective August 22, 2025, while maintaining its Nasdaq listing under symbol "ONCY."
The clinical-stage immunotherapy company cited cost-benefit analysis and U.S. focus as key reasons, with plans to cease Foreign Private Issuer status by January 1, 2026.
The company continues developing pelareorep, an immunotherapeutic agent with Fast Track designation from FDA for metastatic pancreatic and breast cancers.
Oncolytics Biotech Inc., a clinical-stage immunotherapy company developing the novel cancer therapeutic pelareorep, announced its voluntary delisting from the Toronto Stock Exchange (TSX) effective at market close on August 22, 2025. The company will maintain its primary listing on the Nasdaq under the symbol "ONCY."
Strategic Rationale for Delisting
The board of directors determined that TSX delisting serves the company's best interests and those of its shareholders for several strategic reasons. The company already maintains an active Nasdaq listing and intends to continue trading on that exchange. Additionally, Oncolytics will cease to be treated as a Foreign Private Issuer under U.S. federal securities laws effective January 1, 2026, and is considering future re-domiciling to the United States.
The decision reflects a cost-benefit analysis showing that maintaining a secondary TSX listing no longer justifies the direct and indirect expenses, given Oncolytics' U.S. operational focus and predominantly American shareholder base.
Continued Access for Canadian Investors
Canadian shareholders will retain the ability to trade their shares on the Nasdaq through brokers with U.S.-registered broker-dealer affiliates. The company will continue operating as a reporting issuer across Canadian provinces and territories. Under Section 720(b) of the TSX Company Manual, shareholder approval was not required since the shares remain listed on an acceptable alternative market.
Pelareorep Development Program
Oncolytics continues advancing pelareorep, an intravenously delivered immunotherapeutic agent that converts immunologically "cold" tumors "hot" through activation of innate and adaptive immune responses. The drug has demonstrated promising results across multiple cancer types, including first-line pancreatic cancer (搜索) studies, two randomized Phase 2 studies in metastatic breast cancer (搜索), and early-phase studies in anal and colorectal cancer (搜索).
The company is currently advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers. Both indications have received Fast Track designation from the FDA, along with development programs for other gastrointestinal tumors (搜索).
Strategic Partnership Initiatives
Oncolytics is actively pursuing strategic partnerships to accelerate development timelines and maximize commercial impact of pelareorep. The company's focus on partnership development aligns with its strategic shift toward U.S.-centric operations and regulatory pathways.